Weekly Research Analysts’ Ratings Updates for Elevance Health (ELV)

Several brokerages have updated their recommendations and price targets on shares of Elevance Health (NYSE: ELV) in the last few weeks:

• 10/27/2026 – Elevance Health had its price target raised by Wells Fargo & Company from $473.00 to $492.00. They now have an “overweight” rating on the stock.
• 10/23/2026 – Elevance Health was given a new $490.00 price target by Mizuho.
• 10/23/2026 – Elevance Health had its “neutral” rating reaffirmed by The Goldman Sachs Group. They now have a $451.00 price target on the stock.
• 10/23/2026 – Elevance Health had its price target raised by TD Cowen from $465.00 to $495.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Elevance Health had its price target raised by UBS Group from $460.00 to $523.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Elevance Health had its price target raised by Royal Bank Of Canada from $424.00 to $455.00. They now have a “sector perform” rating on the stock.
• 10/22/2026 – Elevance Health had its price target raised by Guggenheim from $460.00 to $485.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Elevance Health had its price target raised by Barclays from $469.00 to $472.00. They now have an “overweight” rating on the stock.
• 10/22/2026 – Elevance Health had its price target raised by Morgan Stanley from $404.00 to $449.00. They now have an “equal weight” rating on the stock.
• 10/22/2026 – Elevance Health had its price target raised by Robert W. Baird from $393.00 to $406.00. They now have a “neutral” rating on the stock.
• 10/12/2026 – Elevance Health had its price target raised by Guggenheim from $455.00 to $460.00. They now have a “buy” rating on the stock.
• 10/7/2026 – Elevance Health had its price target raised by Barclays from $457.00 to $469.00. They now have an “overweight” rating on the stock.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be given a $1.72 dividend. The ex-dividend date is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%.

Insider Transactions at Elevance Health

In related news, CFO Mark Kaye sold 10,584 shares of Elevance Health stock in a transaction that occurred on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the sale, the chief financial officer directly owned 19,919 shares in the company, valued at $8,766,949.47. This trade represents a 34.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.34% of the stock is currently owned by insiders.

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.